Report Overview
The Global Opioid Induced Constipation Treatment Market reached US$ 1,241.90 million in 2025 and is expected to reach US$ 1,835.00 million by 2033, growing at a CAGR of 5.0% during the forecast period 2026-2033.
Opioids are effective for treating and managing pain, but using them frequently can lead to constipation. This can affect comfort, health, and quality of life. According to an article in the BMJ, among people who use opioids for pain relief, constipation affects 52 % of those with advanced cancer and 87% of those with a terminal illness.
Market Strategic Insights
| Metrics | Details |
| Market CAGR | 5.0% |
| Segments Covered | By Distribution Channel, By Route of Administration, By Drug Class, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights Request free Sample
Market Dynamics
The major driving forces used constipation, recent drug approvals and robust pipeline, and rising opioids for chronic pain.
The rising prevalence of opioid-induced constipation is expected to drive market growth.
The rising prevalence of opioid-induced constipation is expected to boost the market. For instance, in a study carried out in Spain with 317 ambulatory patients undergoing treatment with different opioids for chronic pain, whether caused by cancer or not, 94.6% of patients reported at least one symptom of Opioid-induced bowel dysfunction and constipation. The most frequent symptom was constipation (91.6%). Although opioids are highly efficacious for treating acute and chronic pain, they can also cause several significant side effects. One of the most commonly reported side effects of opioid use is opioid-induced constipation. According to the National Institute of Health, 40–80% who were prescribed opioid drugs experienced constipation due to drug consumption. Thus, the increasing prevalence of opioid-induced constipation is driving the market.
The low diagnosis rate and stiff competition from standard laxatives are restraining the market's growth.
The low diagnosis rate is likely to hamper the market. For instance, clinicians lack awareness about opioid-induced constipation in patients on opioid therapy in Spain, one of the major factors hampering the growth of the opioid-induced constipation market. Even if the clinicians are aware, they do not ask patients about constipation. Usually, patients might feel ashamed to disclose their constipation-related symptoms to clinicians. The major restraint hampering the market's growth is the absence of universal diagnostic criteria for opioid-induced constipation.
Industry analysis.
The Spain opioid-induced constipation market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing, and pipeline analysis.
Market Segment Analysis
The antibiotics segment is expected to dominate the Spain opioid-induced constipation market throughout the forecast period (2022-2029).
The Mu-Opioid Receptor Antagonists are expected to grow rapidly over the forecast period (2022-2029). Mu-Opioid Receptor Antagonists (including PAMORAs) are designed to antagonize the intestinal activity of opioids while preserving their systemic effect. Some Mu-Opioid Receptor Antagonist drugs include Naldemedine, Naloxegol, and Methylnaltrexone. The increasing cases of cancer and chronic pain disorders such as arthritis fuel the Mu-Opioid Receptor Antagonists segment growth as these drugs can be used for OIC treatment in patients with chronic pain related to cancer and non-cancer pain. For instance, according to World Cancer Research Funds International, in 2020, there were around 260,455 new cancer cases and 112,335 deaths due to cancer. Thus, the Mu-Opioid Receptor Antagonists are estimated to dominate the Spain Opioid-Induced Constipation market throughout the forecast period.
Market Key Players
The major players operating in the Spain opioid-induced constipation market are AstraZeneca, Shionogi & Company, Limited, Takeda Pharmaceuticals Company Ltd, and Bausch Health Companies Inc. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the Spain opioid-induced constipation market. For instance, on 11 August 2022, AstraZeneca acquired TeneoTwo, Inc. Also, on January 10, 2022, Takeda Pharmaceuticals Company Ltd announced its plan to acquire Adaptate Biotherapeutics.
Recent Key Developments – Global Opioid-Induced Constipation Market (2026–2025)
✅ 2026: Growing industry emphasis on advanced OIC therapeutics and targeted drug classes, particularly mu-opioid receptor antagonists, with companies focusing on improving efficacy and minimizing side effects to enhance patient compliance and treatment outcomes.
✅ 2026: Expansion of the global OIC treatment market driven by increasing opioid usage for chronic and cancer-related pain management, with a significant patient base requiring long-term constipation management solutions.
✅ 2025: Rising investment in research and development of novel OIC drugs and combination therapies, with pharmaceutical companies accelerating clinical pipelines to address unmet needs in chronic pain patients.
✅ 2025: Increasing awareness and diagnosis of opioid-induced constipation, supported by improved clinical guidelines and physician education, leading to higher treatment adoption rates globally.
✅ 2025: Growth in demand for oral formulations and retail pharmacy distribution channels, driven by patient convenience and accessibility, strengthening market penetration across both developed and emerging regions.
Takeda Pharmaceutical Company Limited.
Overview:
Takeda Pharmaceutical Company Limited is a multinational pharmaceutical company with partial American and British roots. It is one of Asia's largest pharmaceutical top 20 companies and was founded in 1781 by Chobei Takeda.
Product Portfolio:
Takeda Pharmaceutical Company Limited’s product portfolio for opioid-induced constipation treatment has AMITIZA (lubiprostone).
The opioid-induced constipation market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages
